Reduced glutamatergic signaling is a final common denominator of a number of disorders that reduce cognitive ability, including mild cognitive impairment, Alzheimer's disease, schizophrenia, ADHD, narcolepsy, autism, depression, schizophrenia and Parkinson's disease. The best hope for improving the quality of life of afflicted individuals may lie with mitigating the most debilitating symptoms, and certainly cognitive decline significantly impacts both the quality of life and the ability to contribute to the workforce. Drugs which target AMPA receptors show promise in the treatment of cognitive disorders. In this study, investigators will use a biophysical approach in cells to study AMPA receptor modulation using drugs that target the receptor in many different ways. The goal of this study is to understand how drugs and proteins work together to modulate AMPA receptor activation. This basic molecular and cellular research may better direct future efforts to design AMPA-selective, cognition-enhancing drugs that can be used in clinical populations, including autism.